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for repeatrevascularizationi the 1st year for vesselstreated
by stentingrather than balloonangioplasty.Longer-term(1 to
5 years)clinicalresultsof Palmaz-Schatzstentingare not yet















5 years).However,the rate of repeat revascularizationof the
treatmentsite (targetsite revascularization[TSR])was14.4%,
17.7%and 19.8%at 1,3 and 5 years,respectively,withlate (>1
year)TSRdrivenbyin-stentrestenosisin only3 patients(1.7%).
Ratesof both5-yearsurvival(70.5%vs. 93.4%)and event-free
survival(21.1%vs.63.3%)werelowerforpatientswhounderwent










late eventscan be attributedto the progressionof coronary
diseaseat othersites,ratherthantolatedeteriorationofthestent





late restenosisaftercatheterintervention,but the initialclin-
icalreportsofcoronaryarterystentingin 1987wereplaguedby
high(>20%)acuteandsubacutethrombosis(6).Overthepast
severalyears, stent outcomeshave improvedprogressively
(7,8), culminatingin the recent STRESS(Stent Restenosis
Study)(9)andBENESTENT(BelgianNetherlandsStent)(10)
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has been reported to have a higher successrate and lower
restenosisrate than those historicallyreported for balloon
angioplasty(11).Whereasthesefavorableresultsare basedon
measurementsat 6 to 9 months,the longer-term(1to 5years)
resultsofPalmaz-Schatzstentingarenotwellestablished.Late
migrationof the stent, metal fatigue,endarteritisand late
restenosishave each been proposedas potentiallong-term
complicationsof coronarystent implantation(12).

































ered for stentingif they had significant(>70%) diameter
stenosisin a nativecoronaryarteryor SVG accompaniedby
evidenceof myocardialischemia.Exclusioncriteriaincluded
contraindicationto antiplateletor anticoagulationtherapy,
poor distal runoff,small (<2.75 mm) or diffuselydiseased
vessels.Allpatientsprovidedwritteninformedconsent.
Pharmacologicprotocol.All patients received soluble,
non-enteric–coatedaspirin(325mg, continuedindefinitely),
dipyridamole(200mgdaily,continuedfor 1to 2 months)and
a calciumantagonistbefore the procedure.In addition,low
molecularweightdextran(Dextran40)wasgivenat a doseof
100ml/hfor2h beforestentingandat a doseof50ml/hduring
and after the procedure,for a total volumeof 1 liter. A
first-generationcephalosporinor vancomycinwasstarted1 h
before the procedureand continuedfor 48 h. During the
procedure,10,000U of heparin was administeredintrave-
nously,withadditionalheparingivento maintainan activated
clottingtime>300s.Therapywithwarfarinwasstartedtheday
of theprocedureandcontinuedfor 1to 2months.Au infusion
of heparin was discontinuedonce the prothrombintime
reached16to 18s.
Stent implantation.All patients receivedPalmaz-Schatz
stents (Johnson& JohnsonInterventionalSystems,Warren,
NewJersey)througha varietyof deliverytechniques(hand-
crimped bare stents, 6F SchneiderTeleguide,Johnson &
JohnsonInterventionalSystemsStent Delive~ System).Le-
sionswerepredicatedwiththe useof a 2.5-mmballoon.After
deploymentof the stent, adjunctivepostdilationwas per-
formed (1.1:1balloon/arteryratio), to achievea visually-
estimatedangiographicresidualdiameterstenosis<1O%.Cre-
atine kinase, MB fraction (CK-MB)levelswere routinely





rent angina,or anyrevascularizationi cludingcoronaryartery
bypassgrafting(CABG) or percutaneousangioplasty).All
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revascularizationswerecategorizedaccordingto whetherthey
involvedthe targetsite (TSR)or targetvessel(TVR).Target
vesselrevascularizationwas definedas any revascularization
that involvedthe targetvessel,andtargetsiterevascularization
wasdefinedasanyrevascularizationonthe targetvesseldriven
bystenosiswithinthe indexstentor within5 mmon eachside
(proximaland distal)of the stented area. Death from any
causewas consideredan end point. Clinicalfollow-upwas
availablefor the entire cohortof 175patients,and included
follow-upof =4 years in 173 patients (99%), excluding2
patientswhowerelost-to-follow-upat 22and40monthsafter
the indexprocedure.At last contact,both of these patients
were event-free.Survivaland event-freesurvivalwere calcu-
lated from the date of the procedureto the date of death,
adverseeventor lastfollow-up.
Angiographicanalysis.Augiographywasperformedin two
orthogonalviews.Each stented lesionwas measuredfrom
an opticallymagnifiedcine frame showingthe lesion in its





Factors analyzedand statisticalmethods.Data are ex-
pressed as mean value * SD. Continuousvariableswere













patients who underwentplacementof 194 Palmaz-Schatz
corona~ stentsin 185vessels(left anteriordescendingcoro-
naryartery39[21%],leftcircumflexcoronaryartery19[10%],
right coronaryartery 68 [3790]and SVG 59 [32910]).Their
baselinecharacteristicsare summarizedin Table1.The mean
age was 59 t 11 years;34 patients (19.490)were women.
Diabetes mellituswas present in 29 patients (16.7%),37
patients(21.3%)had a recentmyocardialinfarction(within6
weeks) and 115 patients (66.5%)presented with unstable
angina.Previouscoronaryartery bypassgraftinghad been
performedin 53 patients (30.6%).The majorityof lesions
(57.7%) represented recurrence after one or more prior
catheterinterventions.
Acute procedural outcome.Although these procedures
wereperformedearlyin the investigationalphaseof coronaq
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valuet SDor number(Ye) of patientsor vessels.CABG= coronaryartery
bypassgrafting.
stenting,the immediateresultsgenerallycomparefavorably
with more recent experience.Angiographicsuccess(<50%
diameterstenosiswithThrombolysisin MyocardialInfarction
[TIMI]grade 3 flow)was achievedin 173patients(98.9%).
Themeanpreproceduralstenosiswas78* 24%,andthemean
postproceduralstenosiswas–1 t 1%.Thelumendiametersat
baselineand immediatelyafter the procedureare shownin
Figure1. One patientdied8 daysafter the indexprocedure,
yieldinga proceduralmortalityrate of 0.6%. Emergenq
corona~ arterybypassgraftingwasperformedin onepatient
(0.6%)afteran unsuccessfulattemptto stenta post-coronary
angioplastydissection.There were no Q wave myocardial
infarctions,but ninepatients(5.1%)had a non-Qwavemyo-
cardialinfarction(CK-MB>13 IU/dl).Subacutestentthrom-
Figure1. Cumulativefrequency of minimal lumen diameter at base-
line, after stent implantation and at follow-up.









Anginaat conclusionof study 50(28.6%)
Datapresentedarenumber(%)ofpatients.CAf3G= coronaryarterybypass
grafting;PTCA= percutaneoustransluminalcoronaryangioplasty.












3.1months.The mean percentstenosison follow-upangiog-
raphywas35 ? 26Y0.Angiographicrestenosis(=5070diame-
ter stenosis)wasobservedin 43(26.1%)of 165stentedvessels.
The lumendimensionsat follow-upangiographyare shownin
Figure1.Of 24patients(14%)whodidnotundergofollow-up
angiography,19patientshavebeen followedup clinicallyfor
=4 yearsand haveremainedfree of all adverseeventsinclud-
ingrepeatrevascularization.The remainingfivepatientswith-
out angiographicfollow-updied(0.3,3,5,24 and32monthsof
clinicalfollow-up,respectively).Oneof the fivediedof cancer
(0.3month),oneofcomplicationsofa myocardialinfarctionin
a distributiondistinctfromthe stentedvessel(24months)and
three suddenlyof undeterminedcause (3, 5 and 32 months,
respectively).
Late clinicalfollow-up.Late clinicalfollow-upwas avail-
ableforallpatientsat54f 17months,with=4 yearsofclinical
follow-upavailablefor 173(99%).Data on all eventsat last
follow-upare showninTable2.At theconclusionofthestudy,
24 patients (13.7%)had died after a mean of 21.3 ~ 15.2
months(median20).Majorevents(death,myocardialinfarc-
tion and revascularization)had occurred in 87 patients
(49.7%)after a mean of 17.4t 15.4months(median10.4).
Theseeventsincludedrepeat revascularizationin 69 patients
(39.4%)aftera meanof 14.9* 14.2months(median7.2)and
myocardialinfarctionin 22 patients(12.6’%0)after a mean of
22.2t 14.7months(median20,1).At lastcontact,120patients
(68.6%)werealiveand free of angina.
Of the 87patients(49.7%)who had repeat revasculariza-
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of the repeat revascularizationprocedures.Whereaseightof
theseTSReventsoccurred>1 year(mean28.5* 12months,
median21.6months)after the indexprocedure,only three
patients(1.7%)had in-stentrestenosisthat developedafter
documentedpatencyon 6-monthfollow-upangiography.The
remaininglate TSR eventswere performedon noncritical
in-stentlesions:A 50%in-stentstenosisin an SVGstentwas
treatedafterstentinga newdistal95%stenosis;a stentplaced
forprogressivedistaldiseasewasconsidereda TSRbecauseit
overlappedthe indexstent. In the remainingthree patients,








p < 0.001)was the onlyindependentpredictorof latemortal-
ity.Theprobabilityoffreedomfrommyocardialinfarctionwas
95.9%,89.2%and 86.6%,respectively,1, 3 and 5 years.The
cumulativeprobabilityofevent-freesurvivalwas74.3Y0,58.290
and 50.790,respectively,at 1, 3 and 5 years after the index
procedure.Diabetesmellitus(hazardsratio2.1,p = 0.003)and
prior CABG (hazardsratio 2.6, p < 0.001)were the only
independentpredictorsof adverseevents.Figure 3 shows
significantlybetter survival(97.6Y0vs. 90.470at 1 year and
93.4%vs.70.5%at 5years,p < 0.0001)andevent-freesumival
(76.4%vs.69.2%at 1yearand63.3%vs.21.1%at 5years,p <
0.0001)for nativecoronarystentingthan for SVG stenting
(p< 0.0001).
The cumulativeprobabilityof repeat revascularization,
targetvesselrevascularizationandTSRare depictedin Figure
4.Thecumulativeprobabilityofundergoinganyrevasculariza-
tion was 15.6%,24.3%,35.3%and 41.2%,respectively,at 6
months and 1, 3 and 5 years after stent implantation.By
multivariateanalysis,diabetesmellitus(hazardsratio2.4,p <
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The probabilityof TVR was 14.4%,21.4%,27.4%and
31.3%,respectively,at 6 monthsand 1, 3 and 5 years. In
contrast,theprobabilityofTSRwas8.7’ZO,1470,17.lYo,17.7Y0,
18.4%,and 19.8%,respectively,at 6 months,1, 2, 3, 4 and 5
years.Figure5 showsthe cumulativeprobabilityof revascular-
ization,TSR and non-TSRfor nativecoronaryarteryversus
SVGstenting.The probabilityof undergoingrepeat revascu-
larizationwashigherforSVGstentingthanfornativecoronary
arterystenting(25.6Y0vs.23.790at 1yearand67.4Y0vs.31.5Y0




events can be attributed to the progressionof coronarydisease
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vs.8$%at 1yearand45.570vs.12.3Yoat 5 years,p < 0.01),as
the probabilityof TSR wassimilarfor both groups(10%vs.
15.7%at 1year and 21.9%vs. 19.2%at 5 years,p = 0.88).
Discussion
The 1994Food and DrugAdministrationapprovalof the
Palmaz-Schatzstent for electiveprimarycoronaryarteryre-
vascularizationin selectedpatients(15) representeda mile-
stone in the percutaneoustreatmentof coronaryartery dis-
ease.Includingsuch“off-label”usesas treatingrestenosisand
SVGstenting,an estimated20%to 30’%0ofcoronaryinterven-
tions now involvestent placement.The approvaland rapid
acceptanceofstentingcanbe attributedlargelyto theSTRESS
(9) and BENESTENT(10) trials,whichdemonstratedthat,
comparedwith balloonangioplasty,stentingdecreasedboth
the incidenceof angiographicrestenosisand the need for
repeatrevascularization,However,both trialshad a relatively
short (7 to 8 months)follow-upperiod. The editorial(12)
accompanyingpublicationof the resultsof these trials and
subsequentcommentary(USA Today)(16) raised issuesre-
gardingthe longer-termresultsof stenting,withspecificcon-
cerns about the potentialfor late migration,metal fatigue,
endarteritis,late restenosisand other late complicationsof




Comparisonwith other studies. In the presentstudy,the
immediateproceduralsuccessrate was98.9!Z0,whichis com-
parableto that in the STRESS(9) and BENESTENT(10)
trials,aswellas that in otherstentseries(7,11,15),but higher
than the successrate of balloonangioplastyin the STRESS
and BENESTENTtrialsor other angioplastyseries(17-21).
The rates of emergencyCABG and in-hospitalmortality
(0.6%)were similarto the rates reported for other studies
(7,9-11,15).We observedno Q wavemyocardialinfarctions,
whereas,previousstentseries(9,10)reporteda 0.870to 2.9%
rate of postproceduralQ wavemyocardialinfarction.How-
ever,our5.l!ZOrate ofpostproceduralnon-Qwavemyocardial
infarctionwashigherthanthatreportedintheSTRESS(2.5%)
(9) and BENESTENT(2.3%)(10)trials,and this difference
may reflectour treatmentof SVG lesionsas well as closer
monitoringof postproceduralCK-MB in our series. The
vascularcomplicationrate in our patientswas alsohigh(but
consistentwith STRESSand BENESTENTrates), reflecting
aggressiveanticoagulationand sheath removal techniques
prevalentat that time.The angiographicrestenosisrate in our
serieswas26.1%,midwaybetweenthat seen in the STRESS
(31.6%)and BENESTENT(22%)trialsand lowerthan the
34%restenosisrate reportedwithSVGstentingin the Multi-
centerRegistry(11).
Completeclinicalfollow-upon ourcohortover4 to 6years
showsan overallsurvivalrate of 95.4Y0,87.990and 86.7’%0,
respectively,at 1, 3 and 5 years. This reflectsa 3%/year
mortalityrate typicalof coronaryartery disease.Survival,
however,wassignificantlylowerfor patientswho underwent
SVG rather than nativecoronaryartery stenting(90.4%vs.
97.6%at 1yearand 70.5%vs.93.4%at 5 years,p K 0.0001).
Theevent-freesurvivalratewas74.3%at 1year,whichislower
thanthe 80.5’%0and79.9fZ0event-freesurvivalratesin the stent
armof the STRESS(9)andBENESTENT(10)trialsat 7 to 8
months.This differenceprobablyreflects our inclusionof
patientsundergoingtreatmentof restenoticand SVGlesions
with their attendant lower event-freesurvivalrate (22). In
contrast,event-freesumivalat 8 monthsafternativecoronary
vesselstentingwas78Y0in our study,fullycomparableto that
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seenin the STRESSandBENESTENTtrials.Thisevent-free
suwivalrate is higher than historicallyreported for other
percutaneousrevascularizationdevices.In the CoronaryAn-
gioplastyVersusExcisionalAtherectomyTrial (CAVEATI)
(23), the l-year event-freesurvivalrate after balloonangio-
plastyand directionalcoronaryatherectomywas 66.1%and
53.5%,respectively.The l-year event-freesurvivalrate after
balloonangioplastyin the 1985-1986NationalHeart, Lung,
and Blood Institute registrywas 66Y0(18). However,the
event-freesurvivalrate decreasedfurther (58.27oat 3 years
and50.7Y0at 5years)in ourcohort,potentiallysupportingthe




respectively,at 1,3 and 5 years.However,<50 of procedures
reflectedrepeatinterventionon theindexstentedsegment.The
probabilityof repeat interventionon the stentedsite (TSR)
was thus 8.7’-ZOat 6 monthsand 14910at 1 year, reachinga
plateauat 17.1%to 19.8%over2 to 5 years.Late (>1 year)
TSR was drivenby in-stentrestenosisin onlythree patients
(1.7%of the stentedcohort),withmostotherlate TSRbeing
performedon mild“innocentbystander”lesionsduringproce-
duresaimedprimarilyat treatmentof other segments.These
data confirmedthe data of Kimuraet al. (24),whoreported
3-year follow-upafter Palmaz-Schatzstentingand showed
revascularizationof the targetlesionin only2.lYoof patients
after 14months.In our cohort,the risingrate of overalllate
revascularization(to 41.2$Z0at 5 years)reflectedmostlynon-
TSR (17.6%at 3 yearsand 21.4%at 5 years),indicatingthat
late revascularizationwas performedpredominantlyto treat
progressivediseaseat nontargetsitesratherthan late deterio-
rationat the stentsiteitself.Thiswasparticularlycommonin
patientswho underwentSVG stenting,as we (22) havede-
scribedpreviously.
The stable TSR rate after 1 year thus argues strongly
againstthe suggestionthat stentingsimplydelaysrather than
preventsrestenosis(12),withno indicationof late deteriora-
tionofthe stentedsite.It alsosupportsthe long-termsafetyof
stenting.However,eventhebestlong-termstentresultsdonot
protect againstprogressionof diseaseat other sites,particu-
larlyin patientsundergoingstentingof SVGlesions.
Limitationsof the study.There are several important
limitationsto thisstudy.Palmaz-Schatzstentingin thisgroup
of patientswas performedearly in our experiencewith this
device.It predatedroutinehighpressurepostdilationof the
stent, intravascularultrasoundguidanceand reducedantico-
agulationregimens,which may have improvedimmediate
resultsor long-termoutcomeof thisprocedure.Furthermore,
the studypatientsrepresenta relativelyselectedgroupwith
respect to lesion morphology,severityof coronary artery
diseaseand comorbidity.Stentingin other patient subsets
(higherriskanatomy,abruptclosureafteruseofotherdevices
and acute myocardialinfarction)may have differentproce-
duralandlong-termoutcomes.In addition,becausethisstudy
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waslimitedto clinicalfollow-up,subclinicalstent-relatedprob-
lems were not investigated.Additionalfollow-up(e.g., 10
years)maydisclosethedevelopmentofstent-relatedproblems,
but thisappearsunlikelyin lightof the 4- to 6-yeardata.
Conclusions.Palmaz-Schatzstentingresultinbetterimme-
diateandlong-termresultsthandoesballoonangioplasty.The
long-term(4- to 6-year)outcomeof Palmaz-Schatzstenting
showsstabilityof the treatedlesion.Mostongoinglate events
can be attributed to the progressionof corona~ disease
elsewhere,whichwouldnot be preventedby even a perfect
(O%restenosis)device.Therewasno evidenceof late clinical
deteriorationof the stentresultitselfat 4 to 6years,a tiding
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